American Academy of Dermatology updates guidelines for primary cutaneous melanoma

January 11, 2019
The American Academy of Dermatology released new guidelines on melanoma treatment. The guidelines address areas such as melanoma in pregnancy and…

Roswell Park immunotherapy expert honored for melanoma research

January 11, 2019
Igor Puzanov, MD, MSCI, FACP, received the Melanoma Foundation Award for outstanding and lifelong

FDA News

FDA approves Vitrakvi for solid tumors with NTRK gene fusion

November 27, 2018
The FDA granted accelerated approval to larotrectinib for the treatment of adults and children with solid tumors that have a neurotrophic receptor…

Meeting News

Triple combination appears safe, effective for advanced BRAF V600-mutant melanoma

November 8, 2018
NEW YORK — The addition of spartalizumab to dabrafenib and trametinib appeared safe and effective for previously untreated patients with…


Melanoma surveillance could benefit patients with chronic lymphocytic leukemia

November 5, 2018
Patients with chronic lymphocytic leukemia or small lymphocytic lymphoma could benefit from active melanoma surveillance, according to study results…

In the Journals

Dabrafenib-trametinib combination shows durable RFS benefit in BRAF V600-mutant melanoma

November 2, 2018
Adjuvant treatment with dabrafenib plus trametinib demonstrated a durable RFS benefit compared with placebo for patients with resected stage III BRAF…

In the Journals

Frequently eating organic food may lower cancer risk

October 22, 2018
Researchers observed a significant reduction in overall risk of cancer among individuals who consumed organic food at a high frequency, according to…


Tinder-style app helps medical students identify melanoma

October 17, 2018
A smartphone app may help medical students more accurately differentiate melanomas from benign skin lesions, according to study results published in…


Patient age influences response to immunotherapy for melanoma

October 5, 2018
Age should be a consideration when predicting response to immunotherapy for melanoma, according to study results published in Clinical Cancer

FDA News

FDA approves Libtayo, first drug specifically for advanced cutaneous squamous cell carcinoma

September 28, 2018
The FDA approved cemiplimab-rwlc for IV treatment of patients with metastatic cutaneous squamous cell carcinoma or locally advanced cutaneous…

In the Journals

Evidence lacking for comparative effectiveness, safety of skin cancer treatments

September 17, 2018
A review published in Annals of Internal Medicine found that although several treatment methods for basal cell carcinoma, including surgery, external…


US military personnel may be at increased risk for skin cancer

August 14, 2018
Active duty military members and veterans in the United States appear to be at elevated risk for melanoma and nonmelanoma skin cancers, according to…


PD-1 blockade provides ‘dramatic advance’ for the treatment of advanced melanoma

August 13, 2018
Immunotherapy agents — including ipilimumab, nivolumab and pembrolizumab — have changed the landscape of the treatment of advanced…

Penn dermatologist receives award for skin cancer research

August 12, 2018
B rian C. Capell , MD, PhD, received a Damon Runyon Clinical Investigator Award. Capell will use the $450,000 research…

In the JournalsPerspective

Regular sunscreen use lowers melanoma risk among young adults

August 2, 2018
Regular use of sunscreen appeared associated with a reduced risk for melanoma among young adults in Australia, according to findings published in…

In the Journals

Adverse skin reactions can occur months after anti-PD-1 treatment

July 18, 2018
Adverse skin reactions to anti-PD-1 therapy for cancer treatment can occur months after therapy initiation and even after patients discontinue…

In the JournalsPerspective

Tanning bed users more likely to examine skin for cancer

July 3, 2018
People who used indoor tanning beds appeared more likely to check their skin for signs of cancer than those who did not tan, according to a research…

FDA NewsVideo

VIDEO: BRAF-MEK combination represents ‘important new therapy’ for melanoma

June 27, 2018
Victor Sandor, MD, chief medical officer of Array Biopharma, spoke with HemOnc Today about the FDA’s approval of a two-drug combination for a…

FDA News

FDA approves Braftovi-Mektovi combination for BRAF-mutated melanoma

June 27, 2018
The FDA approved the combination of encorafenib and binimetinib for the treatment of patients with unresectable or metastatic melanoma with a…


Survivin may be target for immunotherapies in several malignancies

June 27, 2018
Survivin, an inhibitor of apoptosis protein, may be an attractive target for a variety of immunotherapeutic approaches for cancer, according to study…

Healio Jobs